Regeneron Pharmaceuticals Inc vs Stanley Black & Decker, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $740.01 (market cap $76.14B), while Stanley Black & Decker, Inc. trades at $89.66 (market cap $13.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.7× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.77%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| REGN | SWK | |
|---|---|---|
Market Cap | $76.14B | $13.47B |
Volume | 500,239 | 2,859,744 |
Sector | Health | Industrials |
52-Week High | $852.03 | $104.00 |
52-Week Low | $557.73 | $62.12 |
Typical Hold Time | 107 Days | 62 Days |
Enterprise Value | $70.85B | $17.63B |
Dividend Yield | 0.51% | 3.77% |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Stanley Black & Decker (SWK) trades at $88.31, down 1.87% with bearish technical signals. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected 2026 net margin expansion to 4.06%. Recent product launches and margin improvement initiatives under CEO Chris Nelson provide positive catalysts. Valuation appears reasonable with P/E of 21.59 and P/S of 0.88.
SWK offers value with improving profitability and dividend stability, though technical weakness and competitive pressures present near-term risks. Analyst consensus at $93.00 suggests 5.3% upside potential. The stock's recovery depends on successful execution of margin improvement plans and sustained demand in industrial and automotive markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →